Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EHA 2019 /
AlloHCT conditioning intensity in AML in complete remission with residual disease

13th - 16th Jun 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 15.06.19
Views: 613

Dr Christopher Hourigan - National Heart, Lung, and Blood Institute, Bethesda, USA

Dr Christopher Hourigan speaks to ecancer at the 2019 European Hematology Association (EHA) Annual Meeting about a study looking at the impact of allogeneic haematopoietic cell transplantation (alloHCT) conditioning intensity on post-transplant outcomes in acute myeloid leukaemia (AML) patients in complete remission (CR) but with pre-transplant genomic evidence of residual disease.

He explains that normally measurable residual disease in AML is measured by flow cytometry or PCR but, due to the sample, next generation sequencing was used.

Dr Hourigan reports that the patients that had no evidence of a variant detected showed equal survival regardless of which arm of transplant they were in.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation